Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

Summary

This phase I trial studies the side effects and best dose of veliparib when given together with liposomal irinotecan in treating patients with solid tumors. Liposomal irinotecan and veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2017-05-31

Primary completion

2019-11-21

Completion

2023-05-24

Publications

• LaRose M, Connolly RM, O'Sullivan CC, Velcheti V, Vilimas R, Gano K, Bates SE, Pommier Y, Thomas A. A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors. Oncologist. 2023 May 8;28(5):460-e298. doi: 10.1093/oncolo/oyad023.

Drugs

Indications